{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:01:45Z","timestamp":1776261705026,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade\u00ae or Inflectra\u00ae to Flixabi\u00ae in patients with severe refractory sarcoidosis. This single center retrospective cohort study was performed at St Antonius Hospital Nieuwegein, The Netherlands. All patients diagnosed with severe refractory sarcoidosis receiving Remicade\u00ae or Inflectra\u00ae switched to Flixabi\u00ae. The primary outcome was infliximab discontinuation within 6 months of switching. Secondary endpoints included adverse events and loss of clinical, functional, or inflammatory response. Out of 86 patients who switched to Flixabi\u00ae, 79 patients had complete data. None of the 79 patients discontinued infliximab during the first 6 months after switching. Five patients reported an adverse event related to Flixabi\u00ae treatment. We found no change from baseline in FVC, FEV1, DLCOc, 6MWT, and infliximab trough levels 26 weeks after switching. An improvement in physical functioning of 7.3 \u00b1 13.4 points (p = 0.002) with RAND\/SF36 and in biomarker sIL-2R (\u2212475.58 \u00b1 1452.39; p = 0.005) was observed. Switching from originator infliximab Remicade\u00ae or biosimilar infliximab Inflectra\u00ae to biosimilar infliximab Flixabi\u00ae did not result in treatment discontinuation or loss of clinical\/functional\/inflammatory remission.<\/jats:p>","DOI":"10.3390\/cells10020441","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T09:06:10Z","timestamp":1613725570000},"page":"441","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients"],"prefix":"10.3390","volume":"10","author":[{"given":"Bas J. M.","family":"Peters","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Bhatoe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-3727","authenticated-orcid":false,"given":"Adriane D. M.","family":"Vorselaars","sequence":"additional","affiliation":[{"name":"ILD Center of Excellence, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[{"name":"ILD Center of Excellence, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands"},{"name":"Division of Heart and Lungs, Department of Pulmonology, University Medical Centre, 3508 GA Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-2977(98)00058-8","article-title":"Clinical presentation of sarcoidosis in The Netherlands an epidemiological study","volume":"53","author":"Wirnsberger","year":"1998","journal-title":"Neth. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Culver, D.A., and Judson, M.A. (2019). New advances in the management of pulmonary sarcoidosis. BMJ, l5553.","DOI":"10.1136\/bmj.l5553"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman","year":"2001","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000328738","article-title":"Long-term treatment with infliximab in patients with sarcoidosis","volume":"83","author":"Hostettler","year":"2012","journal-title":"Respiration"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/21678707.2013.797891","article-title":"Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment","volume":"1","author":"Vorselaars","year":"2013","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_8","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00296-011-1969-9","article-title":"Cytokine modulators in the treatment of sarcoidosis","volume":"31","author":"Bargagli","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_11","unstructured":"Veltkamp, M., Jonkers, R., and Drent, M. (2015). Position Paper: Vergelijkbaarheid en plaatsbepaling biosimilars van de TNF-alfa blokker Remicade. Dutch Assoc. Pulmonologists."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis","volume":"138S","author":"Schimmelpennink","year":"2018","journal-title":"Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Olsen","year":"2017","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","article-title":"Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: Results of a randomised, double-blind, phase III transition study","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","first-page":"690","article-title":"Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme","volume":"11","author":"Razanskaite","year":"2017","journal-title":"J. Crohns. Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1756284820982802","DOI":"10.1177\/1756284820982802","article-title":"Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab","volume":"14","author":"Fischer","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_20","first-page":"628","article-title":"Evaluating Efficacy, Safety, and Pharmacokinetics After Switching from Infliximab Originator to Biosimilar CT-P13: Experience from a Large Tertiary Referral Center","volume":"26","author":"Bronswijk","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clinthera.2018.11.002","article-title":"Drug Discontinuation in Studies Including a Switch from an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review","volume":"41","author":"Bakalos","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical Switching from Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1212\/WNL.0000000000009526","article-title":"Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar","volume":"94","author":"Kidd","year":"2020","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00415-019-09234-y","article-title":"Infliximab biosimilar for treating neurosarcoidosis: Tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment","volume":"266","author":"Riller","year":"2019","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fmed.2020.00418","article-title":"Are Patients at Risk for Recurrent Disease Activity After Switching from Remicade\u00ae to Remsima\u00ae? An Observational Study","volume":"7","author":"Xue","year":"2020","journal-title":"Front. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1080\/19420862.2017.1337620","article-title":"Glycosylation profile and biological activity of Remicade\u00ae compared with Flixabi\u00ae and Remsima\u00ae","volume":"9","author":"Lee","year":"2017","journal-title":"MAbs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/19420862.2017.1305530","article-title":"Drifts in ADCC-related quality attributes of Herceptin\u00ae: Impact on development of a trastuzumab biosimilar","volume":"9","author":"Kim","year":"2017","journal-title":"MAbs"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Magro, F., Rocha, C., Vieira, A.I., Sousa, H.T., Rosa, I., Lopes, S., Carvalho, J., Dias, C.C., and Afonso, J. (2018). The performance of Remicade\u00ae-optimized quantification assays in the assessment of Flixabi\u00ae levels. Therap. Adv. Gastroenterol., 11.","DOI":"10.1177\/1756284818796956"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Calender, A., Weichhart, T., Valeyre, D., and Pacheco, Y. (2020). Current Insights in Genetics of Sarcoidosis: Functional and Clinical Impacts. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082633"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.sapharm.2018.05.009","article-title":"The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis","volume":"15","author":"Aladul","year":"2019","journal-title":"Res. Soc. Adm. Pharm."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/2\/441\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:26:10Z","timestamp":1760160370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/2\/441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cells10020441"],"URL":"https:\/\/doi.org\/10.3390\/cells10020441","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]}}}